Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).
about
Current Management of Primary Immune ThrombocytopeniaContemporary management of primary immune thrombocytopenia in adultsThromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis.Childhood Immune Thrombocytopenia: Long-term Follow-up Data Evaluated by the Criteria of the International Working Group on Immune Thrombocytopenic PurpuraT cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy.Splenectomy results in patients with idiopathic thrombocytopenic purpura: 10 years of experience in Turgut Ozal Medical Center.Prognostic factors of response to laparoscopic splenectomy in patients with idiopathic thrombocytopenic purpura.Splenectomy for adult chronic idiopathic thrombocytopenic purpura: experience from a single center in China.Splenectomy for chronic idiopathic thrombocytopenic purpura in children: a single center study in China.Response to splenectomy is durable after a certain point in time in adult patients with chronic immune thrombocytopenic purpura.Long-term follow-up of laparoscopic splenectomy in patients with immune thrombocytopenic purpuraThe use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients.Partial splenic embolization.Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principleLong-term outcomes of a 5-year follow up of patients with immune thrombocytopenic purpura after splenectomyCurrent treatment options for primary immune thrombocytopenia.Immune thrombocytopenia: no longer 'idiopathic'.Therapeutic options for immune-mediated thrombocytopenia.Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopeniaOutcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.Spontaneous improvement of chronic immune thrombocytopenia in children: experience of 56 patients at a single institute.Adverse postoperative outcomes in surgical patients with immune thrombocytopenia.Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile.Alternate considerations for current concepts in ITP.Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia.The effect of rituximab on vaccine responses in patients with immune thrombocytopeniaRituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity.Immune thrombocytopenia: epidemiological and clinical features of 216 patients in northwestern Turkey.Does the site of platelet sequestration predict the response to splenectomy in adult patients with immune thrombocytopenic purpura?Severe romiplostim-induced rebound thrombocytopenia after splenectomy for refractory ITP.CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.Identifying the characteristics, natural behavioral pattern, and response to therapy in ITP in a multi-center population in Sri Lanka.Factors associated with the effect of open splenectomy for immune thrombocytopenic purpura.Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children : Splenectomy in ITP.Platelet count evolution as a predictor of outcome after splenectomy for immune thrombocytopenic purpura.Autoimmune manifestations in aged mice arise from early-life immune dysregulation.Review of the Association between Splenectomy and Chronic Thromboembolic Pulmonary Hypertension.Thrombopoietin receptor agonists (TPO-RAs) in patients with persistent or chronic immune thrombocytopenia (ITP).
P2860
Q26779408-C3FE406E-1EFB-424D-BC95-B4327C1E57EBQ26853680-797C6C3F-8F8A-4B2F-ABDE-D2E2B07CE6CEQ30250259-D3AE7085-F8DF-44BC-A1B7-1D9694AF4724Q30808680-A7DC573F-5E98-4D41-8131-AACF1A7C4210Q33349600-F9725825-1379-4209-8F38-C97DC9AB1895Q33360975-ED167095-2011-43AA-8B70-64D5401F44E3Q33366754-B3A80C1D-5307-430D-B97D-22638C5FE321Q33368706-A4AD787A-E872-4F2F-89BE-82EE92D2A4FBQ33369981-ABE642CE-C9E7-4A3D-B8E7-7AB17E4D25D7Q33370711-C4BEA210-2CC2-4D60-83E9-33BAF249BB1BQ33375708-DEDAC413-E9EB-4E81-A0F5-E813992626D8Q33376574-96E08E82-405C-4704-8F3C-FDD5C7BC0663Q33377537-34B0D3B3-72EB-41FE-BD8F-98BCDAC822B7Q33390001-639414BE-8C18-4BB8-8BE6-C9A7418A5B42Q33393057-45C880BE-9AF3-4C30-9FFD-2266B4674ABBQ33394149-3EE328BE-8F75-49DD-99B5-6D79E72D6757Q33395624-DA60AB87-EB34-4E6E-88B4-5CBD42697BB3Q33399601-1306FD92-F742-4F77-97F5-97C8EB058F56Q33400722-9636B075-8727-4DF8-A614-81CDA85AAF10Q33401100-0529CA7C-63ED-4831-B144-D3BA17DA0673Q33401130-37BEA471-A1A5-4F7B-B7AD-058184A1CBA3Q33401321-846960D5-EB88-4C0E-A659-A438644048D0Q33404073-30B949BD-BB7A-4782-89C8-FC4778887F98Q33405515-D5FE2AD1-087F-44BD-8C02-F9AF2732944FQ33406838-D17F8E96-8B28-4C47-86EF-CE34FAE0C90EQ33407813-61E2E3E2-A732-417E-93AE-4953481A0D61Q33407831-9DE804FC-7CFE-4988-AD54-F1B2A6A3EDDFQ33409067-DB7FF8C7-3EBB-4B22-9043-E8B839C14AF0Q33410348-B1F5FA94-D726-48AC-BE18-32F80F8D918CQ33417741-C52D43BC-7CE5-411C-90F0-FEC39AC01CD1Q33417946-B59C60C2-0142-4A3B-9F58-967CBF9E9F33Q33418259-35C6BCC6-3AF6-4F0A-AF11-638E5ECF76A7Q33423336-7F11EA92-F179-461C-A4D1-0669580A8381Q33430236-349F0A57-2BAC-48D8-9B0A-EE3F5EDD8DA5Q33432631-F9774973-85BF-4CE8-AC15-4C9203E12A75Q33433585-326EB18E-61BC-4C28-AD94-4250C5255E3CQ33436335-1CA7427B-06E7-4200-B8FF-E63837EC76E6Q37624299-35EE7DDA-E0E8-4891-8082-325FB14E5957Q38801779-BE3B364F-6ECE-4042-9978-7E4F42FE6AE0Q47305608-F2C58C8B-FBB7-46EC-B171-46A46B162050
P2860
Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Long term follow-up after sple ...... hrombocytopenic purpura (ITP).
@ast
Long term follow-up after sple ...... hrombocytopenic purpura (ITP).
@en
type
label
Long term follow-up after sple ...... hrombocytopenic purpura (ITP).
@ast
Long term follow-up after sple ...... hrombocytopenic purpura (ITP).
@en
prefLabel
Long term follow-up after sple ...... hrombocytopenic purpura (ITP).
@ast
Long term follow-up after sple ...... hrombocytopenic purpura (ITP).
@en
P2093
P356
P1476
Long term follow-up after sple ...... hrombocytopenic purpura (ITP).
@en
P2093
Amiram Eldor
Austin Giunta
Joseph Schwartz
Melissa D Leber
Shmuel Gillis
P356
10.1002/AJH.10253
P577
2003-02-01T00:00:00Z